Abivax Total Revenue

The latest total revenue for ABVX is $2M as of June 2026. That compares with $3.4M in the prior-year period — down 41.0% year over year. That is below the Healthcare sector average of $12T. Investors often review this figure alongside Abivax's historical trend and sector peers before judging valuation or financial health.

Over the past year, ABVX's total revenue moved from $3.4M to $2M — a 41.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Abivax's operating scale or balance-sheet position.

Against Healthcare companies, ABVX currently prints $2M for total revenue, while the sector average sits near $12T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Abivax's growth, margins, and balance sheet.

A total revenue figure of $2M for ABVX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $12T. Explore the charts below for those layers of context.

After noting ABVX's total revenue ($2M), review year-over-year change from $3.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.